News Outlets Examine Global Health, R&D Aspects Of President’s FY17 Budget Request

The Atlantic: What Is the Point of Joe Biden’s Cancer ‘Moonshot’?
“No one doubts the sincerity of Vice President Joe Biden’s ‘cancer moonshot’ initiative. But is the plan even really a ‘moonshot’? … Whether Biden can really do as much to break down the barriers between academic disciplines, between different drug companies, between drug companies and researchers, and between all of them and the federal government, remains to be seen. But there’s something to be said for the approach…” (Graham, 2/11).

The Hill: Obama Proposes Less Money To Fight World’s Top Infectious Killer
“Less than two months after unveiling a plan to fight multidrug-resistant tuberculosis, President Barack Obama has proposed cutting the U.S. Agency for International Development’s funding to combat the world’s No. 1 infectious killer — by 19 percent. This will be the fourth budget in a row from the Obama administration that calls for a 19 percent cut to tuberculosis funding at USAID. In each of the previous years, Congress rejected that reduction…” (Weber, 2/11).

The Lancet: NIH hopes funding increases will continue
“The U.S. Congress recently approved the largest single increase in funding for the National Institutes of Health (NIH) in 12 years … But almost as soon as NIH supporters stopped cheering, they began to worry about next year’s budget, and the challenge of a new public health threat, Zika virus…” (Jaffe, 2/13).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.